New drug shows promise in shrinking lung tumors before surgery
NCT ID NCT05714891
First seen Nov 20, 2025 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This phase 2 trial tests the drug JDQ443 in people with non-small cell lung cancer before they have surgery. The goal is to see if the drug can shrink tumors and improve outcomes. Only 4 participants are enrolled, so results are very early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 3E4, Canada
-
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9, Canada
-
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7, Canada
-
London Health Sciences Centre Research Inc.
London, Ontario, N6A 5W9, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
The Research Institute of the McGill University
Montreal, Quebec, H4A 3J1, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
-
University Institute of Cardiology and
Québec, Quebec, G1V 4G5, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JDQ443
What this could lead to
If successful, this could identify a new treatment option to shrink lung cancer tumors before surgery, potentially improving outcomes.
What could go wrong
This is a very early, small trial with only 4 participants. The drug may not work as hoped, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.